{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:36:28Z","timestamp":1791765388108,"version":"4.3.4"},"reference-count":147,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Atherosclerotic cardiovascular disease (ASCVD) stands as the leading global cause of mortality. Addressing this vital and pervasive condition requires a multifaceted approach, in which antiplatelet intervention plays a pivotal role, together with antihypertensive, antidiabetic, and lipid-lowering therapies. Among the antiplatelet agents available currently, cilostazol, a phosphodiesterase-3 inhibitor, offers a spectrum of pharmacological effects. These encompass vasodilation, the impediment of platelet activation and aggregation, thrombosis inhibition, limb blood flow augmentation, lipid profile enhancement through triglyceride reduction and high-density lipoprotein cholesterol elevation, and the suppression of vascular smooth muscle cell proliferation. However, the role of cilostazol has not been clearly documented in many guidelines for ASCVD. We comprehensively reviewed the cardiovascular effects of cilostazol within randomized clinical trials that compared it to control or active agents and involved individuals with previous coronary artery disease or stroke, as well as those with no previous history of such conditions. Our approach demonstrated that the administration of cilostazol effectively reduced adverse cardiovascular events, although there was less evidence regarding its impact on myocardial infarction. Most studies have consistently reported its favorable effects in reducing intermittent claudication and enhancing ambulatory capacity in patients with peripheral arterial disease. Furthermore, cilostazol has shown promise in mitigating restenosis following coronary stent implantation in patients with acute coronary syndrome. While research from more diverse regions is still needed, our findings shed light on the broader implications of cilostazol in the context of atherosclerosis and vascular biology, particularly for individuals at high risk of ASCVD.<\/jats:p>","DOI":"10.3390\/ijms25052593","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T04:31:23Z","timestamp":1708662683000},"page":"2593","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["The Role of Cilostazol, a Phosphodiesterase-3 Inhibitor, in the Development of Atherosclerosis and Vascular Biology: A Review with Meta-Analysis"],"prefix":"10.3390","volume":"25","author":[{"given":"Minji","family":"Sohn","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4137-1671","authenticated-orcid":false,"given":"Soo","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41569-021-00663-9","article-title":"Update on the pathophysiology and medical treatment of peripheral artery disease","volume":"19","author":"Golledge","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_3","unstructured":"(2023, September 30). The Top 10 Causes of Death. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1747493017694392","article-title":"Stroke care quality in China: Substantial improvement, and a huge challenge and opportunity","volume":"12","author":"Wang","year":"2017","journal-title":"Int. J. Stroke"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"j5842","DOI":"10.1136\/bmj.j5842","article-title":"Peripheral artery disease","volume":"360","author":"Morley","year":"2018","journal-title":"BMJ"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12955-017-0809-3","article-title":"Health related quality of life among myocardial infarction survivors in the United States: A propensity score matched analysis","volume":"15","author":"Mollon","year":"2017","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1161\/STROKEAHA.113.002201","article-title":"Very low quality of life after acute stroke: Data from the Efficacy of Nitric Oxide in Stroke trial","volume":"44","author":"Sprigg","year":"2013","journal-title":"Stroke"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1093\/eurheartj\/ehi376","article-title":"Diabetes, glucose level, and risk of sudden cardiac death","volume":"26","author":"Jouven","year":"2005","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1161\/CIRCRESAHA.115.306884","article-title":"Vascular Complications of Diabetes","volume":"118","author":"Beckman","year":"2016","journal-title":"Circ. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus\u2014Mechanisms, Management, and Clinical Considerations","volume":"133","author":"Hess","year":"2016","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1161\/CIRCULATIONAHA.118.035289","article-title":"Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine","volume":"137","author":"Patel","year":"2018","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2174\/1381612033453910","article-title":"Cilostazol as a unique antithrombotic agent","volume":"9","author":"Kambayashi","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1074\/jbc.272.11.6823","article-title":"Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3)","volume":"272","author":"Degerman","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s12020-013-0120-y","article-title":"Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without cardiovascular event","volume":"47","author":"Huh","year":"2014","journal-title":"Endocrine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1161\/CIRCULATIONAHA.109.892414","article-title":"The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: Principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: A randomized trial","volume":"121","author":"Katakami","year":"2010","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/01.STR.0000157667.06542.b7","article-title":"Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: The multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis","volume":"36","author":"Kwon","year":"2005","journal-title":"Stroke"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial","volume":"9","author":"Shinohara","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ahj.2007.12.024","article-title":"Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention","volume":"155","author":"Lotrionte","year":"2008","journal-title":"Am. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1093\/eurheartj\/ehn287","article-title":"A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: Results of the OPTIMUS-2 study","volume":"29","author":"Angiolillo","year":"2008","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-015-0364-3","article-title":"Clinical efficacy and safety of cilostazol: A critical review of the literature","volume":"75","author":"Rogers","year":"2015","journal-title":"Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e2210144","DOI":"10.1001\/jamanetworkopen.2022.10144","article-title":"Aspirin for Primary Prevention-Time to Rethink Our Approach","volume":"5","author":"Berger","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.2337\/dc09-1297","article-title":"Aspirin for the primary prevention of cardiovascular events: A systematic review and meta-analysis comparing patients with and without diabetes","volume":"32","author":"Calvin","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1001\/jama.2014.15690","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: A randomized clinical trial","volume":"312","author":"Ikeda","year":"2014","journal-title":"JAMA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Collaborative Group of the Primary Prevention Project","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus","volume":"379","author":"Group","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of Aspirin on All-Cause Mortality in the Healthy Elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"Polypill with or without Aspirin in Persons without Cardiovascular Disease","volume":"384","author":"Yusuf","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1160\/TH16-04-0316","article-title":"Enhanced platelet MRP4 expression and correlation with platelet function in patients under chronic aspirin treatment","volume":"116","author":"Massimi","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27A","DOI":"10.1016\/j.amjcard.2008.11.020","article-title":"Variability in responsiveness to oral antiplatelet therapy","volume":"103","author":"Angiolillo","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamainternmed.2022.1365","article-title":"Whom to Treat for Primary Prevention of Atherosclerotic Cardiovascular Disease: The Aspirin Dilemma","volume":"182","author":"Mora","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.2337\/dc16-S011","article-title":"8. Cardiovascular Disease and Risk Management","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2337\/dc10-0555","article-title":"Aspirin for primary prevention of cardiovascular events in people with diabetes: A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation","volume":"33","author":"Pignone","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jcpt.13284","article-title":"Cilostazol increases adenosine plasma concentration in patients with acute coronary syndrome","volume":"46","author":"Xue","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Yun, S.H., Sim, E.H., Goh, R.Y., Park, J.I., and Han, J.Y. (2016). Platelet Activation: The Mechanisms and Potential Biomarkers. Biomed. Res. Int., 2016.","DOI":"10.1155\/2016\/9060143"},{"key":"ref_42","first-page":"870","article-title":"Adenosine inhibits the rise in intracellular calcium and platelet aggregation produced by thrombin: Evidence that both effects are coupled to adenylate cyclase","volume":"37","author":"Paul","year":"1990","journal-title":"Mol. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11515-008-0098-7","article-title":"The critical roles of cyclic AMP\/cyclic AMP-dependent protein kinase in platelet physiology","volume":"4","author":"Yan","year":"2009","journal-title":"Front. Biol. China"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11239-020-02214-4","article-title":"MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activation","volume":"51","author":"Guarino","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1055\/s-0038-1629920","article-title":"Impact of Multidrug Resistance Protein-4 Inhibitors on Modulating Platelet Function and High on-Aspirin Treatment Platelet Reactivity","volume":"118","author":"Alemanno","year":"2018","journal-title":"Thromb. Haemost."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2014-08-595942","article-title":"The ABCC4 membrane transporter modulates platelet aggregation","volume":"126","author":"Cheepala","year":"2015","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1160\/TH12-04-0232","article-title":"Reduction of cAMP and cGMP inhibitory effects in human platelets by MRP4-mediated transport","volume":"108","author":"Borgognone","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2169\/internalmedicine.56.7760","article-title":"Dual Therapy with Aspirin and Cilostazol May Improve Platelet Aggregation in Noncardioembolic Stroke Patients: A Pilot Study","volume":"56","author":"Ohnuki","year":"2017","journal-title":"Intern. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCINTERVENTIONS.109.880179","article-title":"Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study","volume":"3","author":"Jeong","year":"2010","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/MED.0b013e32807f2ad9","article-title":"Antiplatelet therapy in type 2 diabetes mellitus","volume":"14","author":"Angiolillo","year":"2007","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ccd.24416","article-title":"Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: Impact of high on-treatment platelet reactivity and diabetes mellitus status","volume":"81","author":"Capranzano","year":"2013","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10557-007-6036-0","article-title":"The cardioprotective effect of a statin and cilostazol combination: Relationship to Akt and endothelial nitric oxide synthase activation","volume":"21","author":"Manickavasagam","year":"2007","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000138400","article-title":"Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle","volume":"36","author":"Tanaka","year":"1988","journal-title":"Pharmacology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1210\/en.2003-1430","article-title":"Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells","volume":"145","author":"Wu","year":"2004","journal-title":"Endocrinology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2174\/157489009787260025","article-title":"A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy","volume":"4","author":"Dindyal","year":"2009","journal-title":"Recent. Pat. Cardiovasc. Drug Discov."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S0024-3205(01)01258-9","article-title":"Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta","volume":"69","author":"Nakamura","year":"2001","journal-title":"Life Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vph.2015.01.002","article-title":"Cilostazol induces vasodilation through the activation of Ca(2+)-activated K(+) channels in aortic smooth muscle","volume":"70","author":"Li","year":"2015","journal-title":"Vasc. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1527-3466.2001.tb00076.x","article-title":"Cilostazol (pletal): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake","volume":"19","author":"Liu","year":"2001","journal-title":"Cardiovasc. Drug Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00005344-200009000-00011","article-title":"Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication","volume":"36","author":"Liu","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0002-9149(97)00256-7","article-title":"Adenosine and adenosine receptors in the cardiovascular system: Biochemistry, physiology, and pharmacology","volume":"79","author":"Shryock","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Chancharoenthana, W., Leelahavanichkul, A., Taratummarat, S., Wongphom, J., Tiranathanagul, K., and Eiam-Ong, S. (2017). Cilostazol attenuates intimal hyperplasia in a mouse model of chronic kidney disease. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187872"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/00005344-199212000-00009","article-title":"Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture","volume":"20","author":"Takahashi","year":"1992","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/01.HYP.0000158263.64320.eb","article-title":"Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F","volume":"45","author":"Kim","year":"2005","journal-title":"Hypertension"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jvs.2011.07.087","article-title":"Cilostazol suppression of arterial intimal hyperplasia is associated with decreased expression of sialyl Lewis X homing receptors on mononuclear cells and E-selectin in endothelial cells","volume":"55","author":"Takigawa","year":"2012","journal-title":"J. Vasc. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mvr.2004.05.002","article-title":"Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production","volume":"68","author":"Omi","year":"2004","journal-title":"Microvasc. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1081881","DOI":"10.3389\/fphys.2022.1081881","article-title":"Vascular smooth muscle cells in intimal hyperplasia, an update","volume":"13","author":"Deglise","year":"2022","journal-title":"Front. Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/ATVBAHA.111.230987","article-title":"Cilostazol promotes vascular smooth muscles cell differentiation through the cAMP response element-binding protein-dependent pathway","volume":"31","author":"Chen","year":"2011","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.atherosclerosis.2006.01.022","article-title":"Activation of endothelial nitric oxide synthase by cilostazol via a cAMP\/protein kinase A- and phosphatidylinositol 3-kinase\/Akt-dependent mechanism","volume":"189","author":"Hashimoto","year":"2006","journal-title":"Atherosclerosis"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2018.01.019","article-title":"Phosphodiesterase-3 inhibitor cilostazol reverses endothelial dysfunction with ageing in rat mesenteric resistance arteries","volume":"822","author":"Moreira","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ajh.2008.6","article-title":"Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes","volume":"21","author":"Suzuki","year":"2008","journal-title":"Am. J. Hypertens."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s001250050787","article-title":"Role of hepatocyte growth factor in endothelial regulation: Prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor","volume":"40","author":"Morishita","year":"1997","journal-title":"Diabetologia"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Lee, S.J., Lee, J.S., Choi, M.H., Lee, S.E., Shin, D.H., and Hong, J.M. (2017). Cilostazol improves endothelial function in acute cerebral ischemia patients: A double-blind placebo controlled trial with flow-mediated dilation technique. BMC Neurol., 17.","DOI":"10.1186\/s12883-017-0950-y"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0002-9149(03)00458-2","article-title":"Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris","volume":"92","author":"Watanabe","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1007\/s12035-022-03024-w","article-title":"Cilostazol Alleviates NLRP3 Inflammasome-Induced Allodynia\/Hyperalgesia in Murine Cerebral Cortex Following Transient Ischemia: Focus on TRPA1\/Glutamate and Akt\/Dopamine\/BDNF\/Nrf2 Trajectories","volume":"59","author":"Zaki","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/jcp.25930","article-title":"NLRP3 inflammasome: Its regulation and involvement in atherosclerosis","volume":"233","author":"Hoseini","year":"2018","journal-title":"J. Cell Physiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","article-title":"NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis","volume":"122","author":"Grebe","year":"2018","journal-title":"Circ. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00210-022-02233-3","article-title":"Cilostazol attenuates cardiac oxidative stress and inflammation in hypercholesterolemic rats","volume":"395","author":"Lima","year":"2022","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.biopha.2017.07.143","article-title":"Cilostazol protects mice against myocardium ischemic\/reperfusion injury by activating a PPARgamma\/JAK2\/STAT3 pathway","volume":"94","author":"Li","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.phrs.2007.04.007","article-title":"Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients","volume":"56","author":"Agrawal","year":"2007","journal-title":"Pharmacol. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/dom.13667","article-title":"Effect of cilostazol, a phosphodiesterase-3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study","volume":"21","author":"Lee","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00380-010-0093-1","article-title":"Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up","volume":"26","author":"Ahn","year":"2011","journal-title":"Heart Vessel."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"118882","DOI":"10.1016\/j.lfs.2020.118882","article-title":"Cilostazol mitigates mesenteric ischemia\/reperfusion-induced lung lesion: Contribution of PPAR-gamma, NF-kappaB, and STAT3 crosstalk","volume":"266","author":"Gendy","year":"2021","journal-title":"Life Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jss.2017.02.020","article-title":"Oral administration of cilostazol improves survival rate after rat liver ischemia\/reperfusion injury","volume":"213","author":"Fujii","year":"2017","journal-title":"J. Surg. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1440-1681.2011.05550.x","article-title":"Cilostazol protects the heart against ischaemia reperfusion injury in a rabbit model of myocardial infarction: Focus on adenosine, nitric oxide and mitochondrial ATP-sensitive potassium channels","volume":"38","author":"Bai","year":"2011","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0021-9150(99)00480-3","article-title":"Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats","volume":"152","author":"Tani","year":"2000","journal-title":"Atherosclerosis"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0021-9150(00)00760-7","article-title":"Antiplatelet agent cilostazol potentiates adipocyte differentiation of 3T3-L1 cells","volume":"158","author":"Hirose","year":"2001","journal-title":"Atherosclerosis"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.metabol.2013.09.006","article-title":"The hypolipidemic effect of cilostazol can be mediated by regulation of hepatic low-density lipoprotein receptor-related protein 1 (LRP1) expression","volume":"63","author":"Kim","year":"2014","journal-title":"Metabolism"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/ATVBAHA.117.310309","article-title":"Naturally Occurring Variants in LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1) Affect HDL (High-Density Lipoprotein) Metabolism Through ABCA1 (ATP-Binding Cassette A1) and SR-B1 (Scavenger Receptor Class B Type 1) in Humans","volume":"38","author":"Oldoni","year":"2018","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Ito, H., Uehara, K., Matsumoto, Y., Hashimoto, A., Nagano, C., Niimi, M., Miyakoda, G., and Nagano, K. (2012). Cilostazol inhibits accumulation of triglyceride in aorta and platelet aggregation in cholesterol-fed rabbits. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039374"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/fcp.12195","article-title":"Cilostazol exerts antiplatelet and anti-inflammatory effects through AMPK activation and NF-kB inhibition on hypercholesterolemic rats","volume":"30","year":"2016","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Seo, D.H., Shin, E., Lee, Y.H., Park, S.E., Nam, K.T., Kim, J.W., and Cha, B.S. (2022). Effects of a Phosphodiesterase inhibitor on the Browning of Adipose Tissue in Mice. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081852"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0005-2728(00)00247-4","article-title":"UCP1: The only protein able to mediate adaptive non-shivering thermogenesis and metabolic inefficiency","volume":"1504","author":"Nedergaard","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0002-9149(02)02869-2","article-title":"Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication","volume":"90","author":"Thompson","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1517\/14656566.2011.557359","article-title":"Cilostazol and atherogenic dyslipidemia: A clinically relevant effect?","volume":"12","author":"Rizzo","year":"2011","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/jscd.2000.7216","article-title":"Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction","volume":"9","author":"Gotoh","year":"2000","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1161\/CIRCULATIONAHA.104.530097","article-title":"Coronary stent restenosis in patients treated with cilostazol","volume":"112","author":"Douglas","year":"2005","journal-title":"Circulation"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00029330-200603010-00002","article-title":"A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent","volume":"119","author":"Chen","year":"2006","journal-title":"Chin. Med. J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.amjcard.2007.05.032","article-title":"Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial)","volume":"100","author":"Lee","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jvs.2007.10.009","article-title":"Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects)","volume":"47","author":"Hiatt","year":"2008","journal-title":"J. Vasc. Surg."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(08)70094-2","article-title":"Cilostazol as an alternative to aspirin after ischaemic stroke: A randomised, double-blind, pilot study","volume":"7","author":"Huang","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jacc.2007.11.049","article-title":"Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation in Diabetic Patients)","volume":"51","author":"Lee","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12264-009-6192-2","article-title":"Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke","volume":"25","author":"Guo","year":"2009","journal-title":"Neurosci. Bull."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ahj.2009.01.006","article-title":"Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study","volume":"157","author":"Han","year":"2009","journal-title":"Am. Heart J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jacc.2008.09.020","article-title":"Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication","volume":"53","author":"Soga","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1161\/STROKEAHA.110.609370","article-title":"Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis","volume":"42","author":"Kwon","year":"2011","journal-title":"Stroke"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jacc.2010.10.035","article-title":"A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: Results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial","volume":"57","author":"Lee","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000327036","article-title":"Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): A randomized double-blind non-inferiority trial","volume":"32","author":"Lee","year":"2011","journal-title":"Cerebrovasc. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacc.2010.08.631","article-title":"Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: Results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial","volume":"57","author":"Suh","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1161\/CIRCULATIONAHA.112.000711","article-title":"Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study","volume":"127","author":"Iida","year":"2013","journal-title":"Circulation"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0003319712474113","article-title":"Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation","volume":"64","author":"Gao","year":"2013","journal-title":"Angiology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ahj.2013.08.028","article-title":"Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease","volume":"167","author":"Youn","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000369610","article-title":"Final Results of Cilostazol-Aspirin Therapy against Recurrent Stroke with Intracranial Artery Stenosis (CATHARSIS)","volume":"5","author":"Uchiyama","year":"2015","journal-title":"Cerebrovasc. Dis. Extra"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ahj.2015.12.014","article-title":"Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial","volume":"173","author":"Ueda","year":"2016","journal-title":"Am. Heart J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/1440-1681.12495","article-title":"Low-dose adjunctive cilostazol in patients with complex lesions undergoing percutaneous coronary intervention","volume":"43","author":"Zheng","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/CIRCULATIONAHA.117.030190","article-title":"Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients with High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial","volume":"137","author":"Tang","year":"2018","journal-title":"Circulation"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.amjcard.2017.11.005","article-title":"Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) after Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: From the DECREASE-PCI Trial","volume":"121","author":"Lee","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1474-4422(18)30128-5","article-title":"Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): A multicentre, randomised controlled trial","volume":"17","author":"Kim","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1007\/s00380-019-01421-1","article-title":"Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness","volume":"34","author":"Hong","year":"2019","journal-title":"Heart Vessel."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(19)30148-6","article-title":"Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: A multicentre, open-label, randomised controlled trial","volume":"18","author":"Toyoda","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40256-018-0302-3","article-title":"DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan","volume":"19","author":"Chen","year":"2019","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e022575","DOI":"10.1161\/JAHA.121.022575","article-title":"Dual Antiplatelet Therapy Using Cilostazol in Patients with Stroke and Intracranial Arterial Stenosis","volume":"10","author":"Uchiyama","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e018184","DOI":"10.1161\/JAHA.120.018184","article-title":"Efficacy and Safety of Adjunctive Cilostazol to Clopidogrel-Treated Diabetic Patients with Symptomatic Lower Extremity Artery Disease in the Prevention of Ischemic Vascular Events","volume":"10","author":"Kalantzi","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/1753-0407.13300","article-title":"Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the ESCAPE study","volume":"14","author":"Sohn","year":"2022","journal-title":"J. Diabetes"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Lin, J.L., Tseng, W.K., Lee, P.T., Lee, C.H., Tseng, S.Y., Chen, P.W., Chang, H.Y., and Chao, T.H. (2022). A Randomized Controlled Trial Evaluating Outcome Impact of Cilostazol in Patients with Coronary Artery Disease or at a High Risk of Cardiovascular Disease. J. Pers. Med., 12.","DOI":"10.3390\/jpm12060938"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jamaneurol.2023.1526","article-title":"Isosorbide Mononitrate and Cilostazol Treatment in Patients with Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial","volume":"80","author":"Wardlaw","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/STROKEAHA.120.029454","article-title":"Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis","volume":"51","author":"McHutchison","year":"2020","journal-title":"Stroke"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Muhammad, I.F., Borne, Y., Zaigham, S., Soderholm, M., Johnson, L., Persson, M., Melander, O., and Engstrom, G. (2021). Comparison of risk factors for ischemic stroke and coronary events in a population-based cohort. BMC Cardiovasc. Disord., 21.","DOI":"10.1186\/s12872-021-02344-4"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e002259","DOI":"10.1161\/JAHA.115.002259","article-title":"Long-Term Antiplatelet Mono- and Dual Therapies after Ischemic Stroke or Transient Ischemic Attack: Network Meta-Analysis","volume":"4","author":"Xie","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ahj.2023.06.015","article-title":"Efficacy and safety of cilostazol-based triple antiplatelet therapy compared with clopidogrel-based dual antiplatelet therapy in patients with acute ST-elevation myocardial infarction undergoing percutaneous coronary intervention: A multicenter, randomized, open-label, phase 4 trial","volume":"265","author":"Park","year":"2023","journal-title":"Am. Heart J."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10557-021-07187-x","article-title":"Cilostazol: A Review of Basic Mechanisms and Clinical Uses","volume":"36","author":"Kherallah","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_131","first-page":"CD003748","article-title":"Cilostazol for intermittent claudication","volume":"6","author":"Brown","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0002-9343(00)00569-6","article-title":"A comparison of cilostazol and pentoxifylline for treating intermittent claudication","volume":"109","author":"Dawson","year":"2000","journal-title":"Am. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/153857440203600202","article-title":"Effect of cilostazol in patients with intermittent claudication: A randomized, double-blind, placebo-controlled study","volume":"36","author":"Strandness","year":"2002","journal-title":"Vasc. Endovasc. Surg."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/iwj.12085","article-title":"Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease","volume":"12","author":"Gallelli","year":"2015","journal-title":"Int. Wound J."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jacc.2016.11.008","article-title":"2016 AHA\/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"69","author":"Gornik","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3171\/2012.9.JNS12492","article-title":"Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: A multicenter prospective, randomized, open-label blinded end point trial","volume":"118","author":"Senbokuya","year":"2013","journal-title":"J. Neurosurg."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jphs.2016.04.023","article-title":"Protective effects of cilostazol against hemorrhagic stroke: Current and future perspectives","volume":"131","author":"Takagi","year":"2016","journal-title":"J. Pharmacol. Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1527-3458.2008.00042.x","article-title":"Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury","volume":"14","author":"Lee","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3904\/kjim.2009.24.2.113","article-title":"Cilostazol protects endothelial cells against lipopolysaccharide-induced apoptosis through ERK1\/2- and P38 MAPK-dependent pathways","volume":"24","author":"Lim","year":"2009","journal-title":"Korean J. Intern. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1161\/01.STR.0000221783.08037.a9","article-title":"Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion","volume":"37","author":"Watanabe","year":"2006","journal-title":"Stroke"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/0271678X15621499","article-title":"Cilostazol ameliorates collagenase-induced cerebral hemorrhage by protecting the blood-brain barrier","volume":"37","author":"Takagi","year":"2017","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.brainres.2006.01.088","article-title":"Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion","volume":"1082","author":"Lee","year":"2006","journal-title":"Brain Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.brainres.2015.01.022","article-title":"Neuroprotective effects of cilostazol are mediated by multiple mechanisms in a mouse model of permanent focal ischemia","volume":"1602","author":"Shichinohe","year":"2015","journal-title":"Brain Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/STROKEAHA.121.035766","article-title":"Cilostazol Versus Aspirin on White Matter Changes in Cerebral Small Vessel Disease: A Randomized Controlled Trial","volume":"53","author":"Kim","year":"2022","journal-title":"Stroke"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"28D","DOI":"10.1016\/S0002-9149(01)01719-2","article-title":"Analysis of the cilostazol safety database","volume":"87","author":"Pratt","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1111\/dom.14147","article-title":"Effect of cilostazol on carotid plaque volume measured by three-dimensional ultrasonography in patients with type 2 diabetes: The FANCY study","volume":"22","author":"Lee","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_147","unstructured":"Otsuka (1999). Pletal\u2014Highlights of Prescribing Information, Otsuka."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/5\/2593\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:03:40Z","timestamp":1760105020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/5\/2593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":147,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ijms25052593"],"URL":"https:\/\/doi.org\/10.3390\/ijms25052593","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]}}}